Navigation Links
PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
Date:5/9/2011

TAIPEI, May 9, 2011 /PRNewswire-Asia/ -- PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. announced today the execution of an agreement under which PharmaEngine grants back to Merrimack the rights to develop, manufacture, and commercialize PEP02 (known under the designation of MM-398 by Merrimack) in Asia and Europe, with the exception of Taiwan.  

Under the agreement, PharmaEngine will receive an upfront payment of US$10 million, and is eligible to receive up to an additional US$210 million of milestone payments, as well as tiered royalties on net sales in Asia and Europe.  Merrimack is responsible for all product development costs in the licensed territories, while PharmaEngine retains the exclusive development and commercialization rights in Taiwan, and plays a role in clinical and regulatory activities pursuant to an integrated global development plan.

"We are thrilled to collaborate with Merrimack to advance the development of PEP02 (MM-398).  Drug development is like a relay race; PharmaEngine has developed this drug candidate from preclinical to phase II stages, and we believe that Merrimack is well-positioned to take the baton and accelerate development of this product through global commercialization," said C. Grace Yeh, Ph.D., President and Chief Executive Officer of PharmaEngine. "Today's announcement signifies the commitment of both companies to develop an innovative nanoparticle therapy that addresses significant unmet medical needs for cancer patients who are refractory to available treatments."

About PEP02 (MM-398)

PEP02 is a novel and highly stable nanoliposomal formulation of irinotecan.  PharmaEngine has tested PEP02 in several human clinical studies to date, including four phase I studies and two phase II studies in gastric and pancreatic cancers.  Both phase II studies met their primary endpoints of response rate and 3-month survival.  Data from both studies were recently p
'/>"/>

SOURCE PharmaEngine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
2. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
3. Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference
4. RIKEN and Max Planck Society establish Joint Research Center for Systems Chemical Biology
5. What motivates environmental activists, policymakers? asks new research center
6. Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference
7. Green industry knowledge center introduced
8. Intelligent design: Engineered protein fragment blocks the AIDS virus from entering cells
9. Altitude Research Center wins major Pentagon grants
10. Boston Medical Center receives support from CVS Caremark Charitable Trust
11. National Biophotonic Sensors and Systems Center announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... and more action is needed to ensure safeguards are ... Published in PLOS ONE , researchers from Monash ... meta-analysis - combining results from different studies - to ... these areas, to determine whether they actually protect biodiversity. ... said protecting an area from human exploitation made common ...
(Date:8/27/2014)... mastodons, short-faced bears, giant ground sloths, saber-toothed cats ... 13,000 years ago at the end of the Pleistocene ... been debated by scientists who, until recently, could only ... including UC Santa Barbara,s James Kennett, professor emeritus in ... collision with Earth played a major role in the ...
(Date:8/27/2014)... group of fish began exploring land and evolved into tetrapods ... these ancient fish used their fishy bodies and fins in ... remain scientific mysteries. , Researchers at McGill University published ... fish, called Polypterus , to help show what might ... the water. Polypterus is an African fish that ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2Nanodiamonds are forever 2Nanodiamonds are forever 3Walking fish reveal how our ancestors evolved onto land 2
... NC A leading bat expert with the USDA Forest ... Georgia, Kentucky, North Carolina, South Carolina and Tennessee that she ... that kills bats and appears to be rapidly spreading south ... Ph.D. says WNS has been confirmed in Tennessee, and she ...
... selected as a 2010-2014 Harold Amos Medical Faculty Development Program ... a national program of the Robert Wood Johnson Foundation. ... of North Carolina at Chapel Hill School of Medicine, is ... the award. Harold Amos scholars are selected based on their ...
... in nasal drug delivery systems, is pleased to announce ... its Phase II clinical study investigating the efficacy and ... treatment of migraine. Sumatriptan powder in ... delivery device was highly effective in treating a single ...
Cached Biology News:Deadly fungus threatens 9 bat species in Ga., Ky., N.C., S.C. and Tenn., expert says 2Deadly fungus threatens 9 bat species in Ga., Ky., N.C., S.C. and Tenn., expert says 3OptiNose's novel intranasal sumatriptan product highly effective in treating migraines 2
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised an ... Otter Capital as a significant new partner. Otter Capital’s ... Agriplier™ technology, building on recent compelling field trial results ... meeting, we have been impressed with Otter Capital’s knowledge ... Sobba, President and CEO of GGI. “We look forward ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Lactic Acid  (Biodegradable Polymer, Food & ... & Forecasts to 2019" report to their ... hydroxyl-carboxylic acid with an asymmetrical carbon atom. The ... biodegradable polymer, food and beverage, personal care product, ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3MSC names Mary Beth Loesch President and CEO 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... Inc. (the,"Company") (OTC Bulletin Board: TBIO) today announced financial ... financial results are,presented in the tables that follow. ... profit of $0.2 million or $0.00 per share,for the ... loss of $0.4 million or,$0.01 per share for the ...
... Aug. 14 At the Board of Directors,meeting ... dividend of,$.115 per share. The dividend is payable ... August 31, 2007. About Sigma-Aldrich: Sigma-Aldrich is ... biochemical and organic chemical products and kits,are used ...
... - 17 Percent Quarter-to-Quarter Revenue Gain Evidences Start of Turnaround ... for Core Business ... DelSite Signs Additional Agreements, IRVING, Texas, Aug. 14 Carrington,Laboratories, Inc. (Nasdaq: ... to $6.5 million in the year ago,period. The revenue in the quarter just ended, ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Carrington Reports Second Quarter 2007 Results 2Carrington Reports Second Quarter 2007 Results 3Carrington Reports Second Quarter 2007 Results 4Carrington Reports Second Quarter 2007 Results 5Carrington Reports Second Quarter 2007 Results 6Carrington Reports Second Quarter 2007 Results 7
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
WTAP Antibody...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Biology Products: